Pleopharma has filed a notice of an exempt offering of securities to raise $36,240,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Pleopharma is raising up to $36,240,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Pleopharma
PleoPharma, Inc. was founded in 2019 by two physicians, Ginger Constantine and Jay Constantine, one of whom worked to develop new medications and the other as a practicing clinician. The idea for Pleopharma was spawned when the founders observed several individuals within a short period of time who were in obvious distress and severe discomfort when they were trying to discontinue cannabis use. Like many people at the time, the founders were not aware that a withdrawal syndrome for cannabis existed. They were surprised at the severity of the withdrawal symptoms and the impediment this posed to discontinuing cannabis. In an effort to help, the founders began researching the topic and learned that there was an extensive scientific literature regarding both Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome (CWS). Many potential treatments had been studied; unfortunately, none proved to be effective. In the face of this growing crisis, they set out to find a safe and effective treatment to address this unmet need and therefore formed PleoPharma, Inc.
To learn more about Pleopharma, visit https://www.pleopharma.com/
Pleopharma Linkedin Page: https://www.linkedin.com/company/pleopharma
Contact:
Daniel Cartwright, Chief Financial Officer
610-937-2882
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
